ViferaXS: Funding, Investors & Team (Oct 2026)
Tailored peptide antigens and potent adjuvant formulation drive powerful and specific anti-cancer T cell immune responses.
ViferaXS has raised $13.7M across 1 funding round on record, the most recent a Series A of $13.7M announced in Sep 2026.
That round is above the $6.5M median round size for Germany companies tracked on FundedIQ over the last two years.
ViferaXS Company Profile and Key Stats
Latest funding round on record: Sep 2026.
ViferaXS Funding Rounds
ViferaXS Investors
ViferaXS Founders and Leadership Team
Contact details for the ViferaXS team: 1 of 1 has an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →ViferaXS Funding in Context
ViferaXS' latest round of $13.7M is above the median round in Germany. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ViferaXS in Biotechnology and Tübingen
Companies Similar to ViferaXS
ABLE Labs is a biotechnology company that develops laboratory automation and liquid-handling solutions for…
Ahron.ai is an AI-powered HR technology company that provides an agentic HR platform to connect HR systems,…
Kuro is the AI foundation for general contractors.
Restate build workflows, event-driven applications, and distributed services in a fault-tolerant manner with…
Pakajo is a postal service company specializing in pick and pack, comparison portal, block storage, and…
Voice-first senior companion delivered via tablet and dock with a family app, serving Germany's AgeTech…
Noah Labs is a company that develops AI-based software solutions for healthcare and research, which assist in…
Reverion develops reversible and carbon-negative power plants using patented biogas technology for renewable…
mika is an accounting solution firm that offers monthly bookkeeping, payroll, invoice management, and…
Noxtua, Europe’s sovereign Legal AI.
F13 Technologies provides IT consulting, cloud, AI, cybersecurity, and digital transformation services.
Syte offers banks, estate agents, project developers, planners, and authorities all potential and data on the…
ViferaXS Funding FAQs
What does ViferaXS do?
Tailored peptide antigens and potent adjuvant formulation drive powerful and specific anti-cancer T cell immune responses.
How much funding has ViferaXS raised?
ViferaXS has raised $13.7M across 1 round on record. The most recent is a Series A of $13.7M announced in Sep 2026.
When did ViferaXS last raise funding?
ViferaXS' most recent funding round on record is a Series A of $13.7M, announced in Sep 2026.
Who has invested in ViferaXS?
Investors on record for ViferaXS include Huma, SPRIN-D.
Where is ViferaXS headquartered?
ViferaXS is based in Tübingen, Germany.
How many employees does ViferaXS have?
ViferaXS is in the 1-10 employee band.
When was ViferaXS founded?
ViferaXS was founded in 2022.
About FundedIQ's ViferaXS Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ViferaXS is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.